About Gabrielle Lakusta

Gabrielle Lakusta

Articles

Life Science Investing

Pernix Therapeutics Launches Generic Version of Treximet by Company’s Subsidiary, Macoven Pharmaceuticals

Pernix Therapeutics (NASDAQ:PTX), a specialty pharmaceutical company, announced the launch of an authorized generic version of Treximet® (sumatriptan/naproxen sodium) in the U.S. by the Company’s subsidiary, Macoven Pharmaceuticals, LLC.  Treximet is a prescription medicine that contains sumatriptan and naproxen sodium (a NSAID) and is indicated for the treatment of acute

Life Science Investing

Travelan Revenue Grows Significantly in US and Australia

Immuron (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, is pleased to announce its half year sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan.

As quoted in the press release:
Immuron Marketing Manager

Life Science Investing

ALK’s partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan

ALK (OMX:AKBLF) announced that its partner for Japan, Torii, has gained approval from the Japanese Ministry of Health, Labour and Welfare, to expand the use of ALK’s house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients.

As quoted in the press release:
Henrik Jacobi, ALK’s Executive

Life Science Investing

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing of its previously announced public offering of 13,225,000 of its common shares at a public offering price of $2.00 per common share.

As quoted in the press release:

The total includes 1,725,000

Life Science Investing

Allscripts to sell OneContent business to Hyland

Allscripts (NASDAQ:MDRX) has signed a definitive agreement to sell its OneContent business to Hyland Software, a leading provider of content services solutions to the healthcare industry and beyond. The deal is expected to close in the second quarter once customary closing conditions are satisfied.

As quoted in the press release:
“Hyland has